Merck is also giving Intrexon $25 million in cash to help get the CAR-T programmes going, and says the handover will allow it to focus on its other R&D activities but still maintain an interest in ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

Merck CEO Robert Davis joins 'Squawk Box' to discuss the company's quarterly earnings results, which topped expectations as the company saw strong sales from its top-selling cancer drug Keytruda, ...

This year, pharmaceutical giant Merck (NYSE: MRK) is it: The drugmaker's shares are down by 2% in 2024 while the broader S&P 500 is up by 21%. Even when we zoom out, Merck hasn't performed ...

Merck KGaA’sMRK-1.94%decrease; red down pointing triangle shares jumped after the German company said booming artificial-intelligence demand would help its electronics sales grow faster than ...

Oct 17 (Reuters) - German science and technology group Merck (MRCG.DE), opens new tab is open to more acquisitions for its Life Science business after announcing in May it would buy Mirus Bio for ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Its top-selling treatment, Keytruda, will lose patent protection in a few years. Then Merck will face biosimilar competition and likely see sales slide noticeably. There aren't any obvious ...

Merck KGaA said it’s seeing the beginning of a post-Covid pandemic rebound in life sciences as it reaffirmed the group’s sales and profit guidance for the full year. The German science and ...

Wall Street promptly began trying to weigh the compound’s marketplace odds after Merck & Co. Inc. detailed positive data from the phase IIb/III trial known as MK-1654-004 with clesrovimab, an ...

Merck will face an important patent cliff by the end of the decade. The company has a plan to move beyond it. Competition from a new therapy shouldn't derail Merck's prospects. Even when we zoom ...